Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

Blog

Optimize readiness for MHRA-NICE aligned pathway

Achieve HTA and regulatory success in the MHRA–NICE pathway through early evidence alignment.

Certara2026 年 5 月 1 日

On-Demand Webinar

Compliance? Anywhere, anytime: Automated controlled substance detection and tariff classification at Merck KGaA

Learn how Merck KGaA automates controlled substance detection and HS classification to ensure global compliance…

Certara2026 年 4 月 27 日

Conference

ACS Fall 2026

– – Booth

Certara2026 年 4 月 27 日

Fact Sheet

DIDB® Concomitant Meds Navigator

Explore the Concomitant Meds Navigator withing DIDB - An evidence-based tool within DIDB that helps…

Certara2026 年 4 月 27 日

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

Certara2026 年 4 月 10 日

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

Certara2026 年 4 月 7 日

药物开发

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Optimize readiness for MHRA-NICE aligned pathway

Compliance? Anywhere, anytime: Automated controlled substance detection and tariff classification at Merck KGaA

ACS Fall 2026

DIDB® Concomitant Meds Navigator

ADC dose optimization: Applying model-informed strategies in development

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

订阅时事通讯

快捷链接

解决方案

联系我们